JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - VERASTEM INC
All right, great. Good afternoon, everyone. Thank you, those of you who have joined in the room and on the phone line as well. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today the management team of Veristem Oncology. Especially pleased to Have Michael Bailey in, I think, your first kind of real public showing as the CEO? Yeah, back in the saddle. All right. Awesome. Well, Michael, why don't we just start there? I would love if you can just kind of give a little bit of an intro to yourself, the company, and really kind of like what encouraged you to take the role? Yeah, so thank you very much, Faisal, and thanks for having me here. I'm really looking forward to this discussion and individual discussions with investors. But as far as my background, I'm largely business development, kind of commercial-type history. I've been with companies like Genentech, Aveo, Imclone. most recently with Imklon as their CEO for about 11 years. That subsequently sold to LG. Spent about three years with them after that working on the integration. But to your other part of the question, so what got me excited about Veristem? So I joined the Veristem board in June timeframe. And fast forward to October 14th, the world really changed for Veristem. And as I looked at it as a board member and then given consideration for taking the seat in the CEO, there were kind of three things that really changed on October 14th. One, you know, a wealth of data. Two, a really successful financing. And then three, obviously the opportunity for me to take over as CEO. And I'll kind of unpack each one of those things. So the data, and we'll spend a little bit more time on the 7375 data, really kind of positioned us very clearly as a best-in-class G12D inhibitor. And I think, you know, one of the questions with RevMed and all the excitement that RAS and Q has brought to the table and appropriate excitement is that if you looked at the G12D, which the FDA pulled back the curtain, if you will, their activity was a little less than the G2D, notably because that's a tougher population. And our data in G12B looked really solid that we presented on that day. The other thing I think is really exciting for me and others is the complete responses. We're seeing single-agent complete responses that I think will be game-changing for this whole space. The second thing, I think, is the financing. So a $250 million raise, very strong demand going into that, I thing shows an investor sentiment that's changing and realizing the potential for us kind of going forward. And then the last thing I think is obviously my leadership and, you know, my background being more business development and commercial. What that does really for us is it gives us more optionality. You know, can we commercialize this by ourselves? Are there BD or partnership opportunities? I think all of those things are on the table. Got it. So I want to touch on both of those points, and we have Dr. John Pachter here as well, so we'll definitely get into the G12V data. Before we do that, Michael, on that last point that you made on partnership, like obviously you're sitting on something very interesting and valuable here with respect to the data that you've generated and also the robust development plan that you laid out with plans across all three major indications of pancreatic, colorectal, and lung. How do you think about this from a partnership and value-deriving perspective with respect to what does that look like, what does the right timing look like? And just giving your background and experience here, we'd love your comments on that. Yeah, it's a great question, and the simple answer is not really sure at this point. It's a very rapidly evolving space, and as a company, I think it's really critical to drive shareholder value to really entertain every single option that's out there. Clearly, there's a lot of interest not only from investors, also from partners. But, you know, look, if the best valuation that we can achieve is commercializing ourselves, we need to think about it as what we're really doing here. We would be potentially launching as the first G12D in pancreatic. And, you Know, when you think about that way, it's a little more manageable than if you take that whole scope of all the opportunities in front of us. That's a Little daunting. But just keep in mind, we have to do this stepwise. Got it. Okay. Makes sense. So then let's jump into the data itself then, and John, I want to give you an opportunity here to talk about, in terms of what you guys have presented, you're putting up some of the best response rates seen for a G12D selective inhibitor. Can you remind us what has enabled that from kind of the basis of the molecule itself? Yeah, I'd love to. I think a few pillars to that. I think, first of all, the dual on-off inhibition, which is really important. And G12D is mostly in the on state, but it can go kind of hide out in the off state and come back and cycle and to be able to bind it no matter where it lives is great. And it has to be very potent and really equal potent. Ours is about 15 picomolar for both of those states. There's a long residence time, which also really predicted that we saw all this before we saw any clinical data, mind you, and we predicted that it was a good shot at having the best efficacy for patients with KRS-G12D cancer. So the long response rate or slow off rate, about a 24-hour residence time. The third point is it's extremely selective for KRS-G12D. So I think it lets us dose up with good tolerability. KRS G12D is not responsible for any normal functions in your body. So there are no side effects that would be expected from hitting the target directly. And so that selectivity is really key. And then finally, and I think this has been underestimated, as I look at the RAS space, I think that most inhibitors can't get to maximal inhibition of target for a couple of reasons, depending on the agent. There are some agents where pharmacologically you dose, you know, there's one I'm thinking of, you dose at 600, 900, 1200, you get basically the same exposure. It's flat. It's just a property of the molecule, and that makes it hard to fully hit the target. When you look at waterfalls, you might see on the left side of the waterfall some tumor growth as the best response. If you're fully hitting the target as we are, we're not seeing that tumor growth as the most best response when we go up to 900, which is our go-forward dose. In the case of other agents like the pan-RAS inhibitors, pharmacologically they might be able to achieve better exposure to fully hit the target, but they're limited by the safety profile. Got it. And I want to talk about what you just raised on the safety profile, and I'm going to raise this question in sort of a nuanced way, so bear with me. So obviously your China partner, Genfluid, they've been kind of a half step to one step ahead in terms of data generation. They showed a phase one profile that had this impressive efficacy, but had a good amount of safety baggage with it. You've now shared, as of October, a full set of your phase one data from the US study that look quite a bit better on the safety profile can you you know for investors like where they worry a little bit about is like well is this kind of a spurious finding is this related to limited follow-up how can we actually believe that the safety profiling is as good as what you're seeing in the u.s study what would you say to kind of convince investors of that yeah i think that at this point we have enough data that the first thing i'd say is look at our data and take it at face value for what it is. I think that in China, it's not just the RAS space. It's really broader than that. I've talked to other companies that have global trials where they're patients in China and patients ex-China with other targets, and they've also seen poor tolerability in China. There was an ASCO presentation this year where there were three G12D inhibitors back-to-back all China trials. The third presentation was our agent, but presented by our partner, Genfleet. And in all cases, they had much more toxicity than we see. So I think we've talked to Genfleot a lot about this. We think one possibility is Chinese traditional medicines are extensively used, not always reported. There could be drug-drug interactions with them. That's probably a large part of this. I think there's also a higher background of hepatitis in China, which also could be contributing to the safety profile. Got it. Okay, that makes sense. And then I want to also discuss a little bit on combination strategy because I think that's something that's super interesting here. So your China partner, Genfluid, they reported some pretty interesting provocative early data with cetuximab combination of the drug not only in CRC where cetuxime is obviously used, but also in pancreatic cancer. Can you address two things? One is what is the mechanistic rationale for that in pancreatic? That's something That surprised investors a little bit? And also, what do you see as kind of the value of a chemotherapy-free approach? Yeah, those are great questions, too. So I think there were, on the preclinical side, there were some really compelling data from Channing Durer's lab, who's a leader in the space. In February, there was a really nice paper where they used CRISPR-Cas9 in various pancreatic cancer cells to treat with RAS inhibitors and ask, by knocking out one gene at a time, which one, if you knock it out, best augments the efficacy of the RAS inhibitor. And EGFR was a top hit. And they saw that whenever they treated pancreatic cancer cell lines with the various RAS inhibitors, they always saw an upregulation of phospho-EGFR as a resistance mechanism. We've generated preclinical data where we have combined 7-3-7-5 with cetuximab. In in vivo models, we see regression really nicely when we combine the two. And then clinically, we showed data back in June, some case reports where even at submaximal doses like 400 milligrams, we see that cetuximab, you get a much quicker response and a deep response. So it's playing out nicely, but I agree with you. Our partner, GenFleet, showed a 71% response rate they reported in October in pancreatic, and people have been surprised at that. But I think your second question is a great one, which is, at some point, the RAS inhibitors, and ours especially, are bringing such strong responses. We're still looking at durability, but that's also looking very good. Do we really need to subject patients to something as toxic as fulfirinox, for example? I think we're all trying to move to a chemo-free regimen. And so the cetuximab BS7-375 arm of our planned phase 3 trial in front-line pancreatic would exactly be an example of that. And we're looking at that in our phase 2 and second-line pancreatic as well. Got it. And I think you'll have some data coming up for this combination across both pancreatics and colorectal, if I remember correctly. I know you have, like, I feel like it's about a dozen data catalysts, like coming in the next 12 months. Can you just kind of remind us, specifically for that combination, the cetux combo in colorectal and pancreatic, when we'll be seeing data, and can you just at least high-level set expectations for that? Yeah, I don't want to go into specifics of what data and when exactly, but one thing that we've changed, and it was partly Michael's influence coming in as well, but that is one factor, and also there was a lot of pressure to share data, and we really tried to show discipline getting to October, not dripping out data waiting until we had you know all patients we had all confirmers all the responses were confirmed that we showed we showed intent to treat I think that we're trying to set an example for the field really but now that we've done that we move to a model of presenting more at medical meetings that made sense at that time but now that the data are maturing I think one of the problem with medical meetings initially is you put out an abstract in months later the data mature and you're in your publishing and the abstract lives on but I think at this in this point we've been maturing the data for a while we're now going to turn more to medical meetings so I think there'll be some will we haven't guided to which meetings but I that'll be that'll a nice change for us yeah one thing I'll add to that just John said in the context of kind of moving from an emerging biotech to potentially becoming a leading biotec there's a discipline there's an expectation at the interaction with scientific meetings you know not not necessarily responding to every request for additional data points we've presented a very nice data set at this point and we'll build off that in the appropriate way at the appropriate place got it yeah that makes a ton of sense uh michael uh and then i mean to that point michael like you know you guys have a tonne of data coming like over the next uh you know 2027 time period in your opinion what are the most critical and value inflecting of those data sets? Well, we get this question a lot, and it's kind of like they're all very important. And, you know, our goal is to be as broadly applied as possible. We're starting with PANC, colon, lung cancer. You know, obviously the data that we're targeting with the Phase II readouts during the year I think are going to be really important because those are going to be the basis of any discussions with the FDA on accelerated approval so those those are key data but it you know it will all depend on the strength of the data and it will determine the path forward that we're going right now we are kind of making all the bets and when we will talk just not the sidebar but talk about our cash runway to first half of 28 our cash doorway assumes all the phase two data is read out. As soon as we start phase three data and all that, as soon as мы get ready for commercialization, as long as we fill out the 301 data. So there's a lot going on in that. This is biotech at the end of the day. Hopefully they all work out for the benefit of the patients, but you never know. I think it's important for this audience to really briefly describe the development plan, just to put everything in context. So we've started three phase two trials one in pancreatic one along one colorectal that are second line or second line plus and ideally they would each of them could lead to accelerated approval and that's what we've guided that the pancreatics and colorector will fully enroll by the end of this year the lung is a little bit behind and so in 2027 we should see the readouts to those that we could share with the FDA and with investors in due course and so those will be really important because those could lead to accelerated approval those are not slowing us down relative to starting phase threes that will all be in front line in all the same three indications and we've we've guided that we'll start dosing the first patient by the end of this year in the pancreatic study the phase three and then the the phase threes will come next year as a start for lung and colorectal yeah totally i think that's a point that you know i don't know if anyone if everyone kind of totally appreciates right that like the phase two is like what you're saying is Like, those are shots on goal. Like, it doesn't change the critical path of doing the phase threes? Yes. No, it does not change the path. Got it. Yeah. I think that's something that has some interesting kind of strategic value also that you can kind of go to a potential partner and say, hey, like, these are phase twos. Like, yeah, it's subject to getting the FDA to agree, but we could get accelerated approval, and the phase twas are all going to be in flight within the next, like six or so months. Do you feel like that's appreciated by investors and by potential partners? It's a great question, and I think the timing of potential approvals is an important part. There's other companies that have started Phase 3s before us. We're going to start our Phase 3 in pancreatic by the end of the year. That's not that far behind. No, it's not THAT far behind, but we do have the opportunity to leapfrog if, in collaboration with the FDA, they feel that our Phase 2 data is good enough. Again, as I mentioned, we could be the first G12D on the market. But the other thing, kind of back to your other question about, you know, what's important data, and I think a lot of the data we put out maybe isn't as appreciated as it could be, which is one thing that got me really excited is those CRs. Again, single-agent CRs in a refractory setting. No other product has produced single- agent CRs, and the importance of single-ageant goes beyond just a single-argent use. it goes to combinations. Because when you think about adding on chemotherapy, you're not going to stay on that chemotherapy for potentially your lifetime, which you may have the opportunity to stay on a selective, well-tolerated, effective agent like 7-3-7-5. I think the other thing that I think is very powerful from a strategic value perspective is the phase three study in pancreatic that you guys have aligned on. You put some really interesting design features into that study with respect to overall response as a potential endpoint and crossover. Could you guys talk a little bit about kind of the outcome of the discussions that you had with FDA and kind of getting to this favorable trial design? Yeah, you can take it. Sure. And it was a great discussion. They've been a great partner. I think the starting point is we're getting to a world where you can't offer patients chemo and not have the option to cross over to a RAS inhibitor. I mean, RAS inhibitors work. If they didn't cross over to ours, they could go on to commercial RAS inhibitors. So I think that was the starting point, that in the chemo arm, I should outline that there are three arms planned for the phase three, and the FDA has aligned with us on this design. So the first is our G12D plus an anti-EGFR, which would be a chemo-free regimen, which we were talking about. The second is our D12D with gem-NAP-paclitaxel, which will be the chemocombination. and the third arm is the chemo, which is a choice up to the investigator between gemnapaclitaxel or fulfirinox. And so I think that if they go on the chemowarm, they have the option to get our drug. So really, in all three arms, they can get our drugs, which really should be attractive to patients. Got it. Yeah, and I understand that should kind of help the attractiveness of the study to physicians and to patients in turn. that should help recruitability of the study as well. I'm really intrigued by the overall response rate endpoint that you have. When you talk about alignment with FDA and its potential to seek, like, a project front-runner type of approval, can you just give us a little bit more color on, like what does that actually mean in terms of alignment with the FDA? Because it's a broad term that a lot of companies use in slightly different ways. Well, they agreed that PFS and ORR could be co-primary endpoints and that OS for the first time would be a secondary endpoint. And that's why I was describing the crossover is that the OS no longer would be, you know, as meaningful given that patients could get our drug on any of the three arms. So then, right, all the frontrunners, so those that aren't familiar with Project Frontrunner, The idea is you might get accelerated approval for your response rate and then follow it up with more of a time-based endpoint, like PFS in this case, for full approval. So that's, you know, I don't know that we necessarily hash that all out. It would be a review issue. We'll see what the data look like. But it offers up, that design offers up the possibility that there could be accelerated approval for ORR and later for PFS to get full. And just to build on John's point, the FDA is never going to tell you we'll give you an approval on this. It's a review issue. It's subject to the data, and it's not only got to be statistically significant but also clinically meaningful. They were fine with the endpoints, and did they acknowledge that this could be like ORR for accelerated approval with PFS for the full approval? I don't know that it went there necessarily. I think that the fact that ORR is there brings up that possibility. And that's just really what was groundbreaking was them allowing us to make ORR a co-primary. Got it. Okay. And just so I understand, this is kind of like one of the situations where it's like they'll let you run the study, but you have to kind of come with the data and accelerate approval. Right. Exactly right. It's like a matter of discussion. Exactly right, exactly right. Okay. This is all subject to the phase two data in particular, any kind of accelerated approval. and then the frontrunners, you know, based on what we see in the phase three. Got it. Let me just ask the question like a different way, because I think it's important for investors to kind of appreciate this. I think this has caused a little bit of confusion. So the extent of the alignment that you have with FDA on response rate as a potential approval endpoint in frontline pancreatic cancer, is the extentof that alignment any different than it would be for any other kind of accelerated approval filing, including a later line setting? I mean, I think that just let's just take it at face value that they agreed to 900 as the dose, they agreed to OR and PFS as co-primaries, and they agreed to OS as a secondary endpoint. And I think that's all we should really say that we've agreed to. Maybe said another way, you're kind of getting at, is this a confirmatory study or a pivotal study? And that's also subject to the Phase 2 data. So the key thing is, it is a registration Phase 3 study. But whether that ends up being a confirmatory study or whether it ends up being the basis for approval is subject to what we see in our phase two. I think that's got to be really clear to everybody. Got it. And then with respect to like this idea of like Project Frontrunner as an initiative within the oncology division at FDA, is it a project in the sense that like CNPV was like a project and you had to get selected and had to kind of be in that pathway? or is it simply like an avenue that's available once you generate data? I don't believe it's like a club that you join. I think it's – yeah, we've talked to our regulatory people about that. I think its – it just reflects the design and their desire to speed things up. Yeah, so it's something FDA is saying, like, this is something that can be a path to approval. Generally, it's a path. Interesting. Got it. Okay. And then, Michael, if I can just kind of, you know, give you a hard time on something. Please do. And I feel like John probably knows me as the analyst that gives you guys a hard time. When you say that you kind of have the optionality to kind of potentially commercialize yourself, can I just like kind of politely push back and like ask to kind of kick the tires on that? Sure. Because like the thing is like you're running these three phase, it's an amazing development program, right? You have parallel three phase twos. You're going to have three phase threes. Gigantic undertaking that you're doing. And you're dealing with a lot of people. And you have the data to support doing it. But it's like a billion dollars in development capital right there. Like, why do you think that you could be positioned to do this yourself? Yeah, so let's kind of break that down. There's one part. You're kind of focusing on the development part. I think what I'm introducing here is that we have the commercial capability and now leadership to be able to do this. And, you know, if you look at my history, I've competed with the biggest of the big in markets that were highly, highly competitive. That doesn't scare me. You know, I think it all depends on the data, selling evidence-based medicine, doing the right thing for the patients. Then there's the financing part of it, which I think is what you're alluding to. How do you afford a billion-dollar program? Well, again, it goes back to the you take it step by step. And when I talk about optionality, we'll get the phase two readouts kind of mid-next year, and we'll Get a Read from the FDA on whether we can get accelerated approval. Those are things that are going to, I would imagine, get investor interest. So our access to capital is going to go up, so we don't have to necessarily go to partners to help us fund this. So, you know, that's what I mean about optionality. You really have to kind of break it down. We have multiple potential sources of income or revenue to be it, not revenue, but capital to be able to invest in these programs. and that's what we want to make sure that we're assessing those opportunities in a way that's going to create shareholder value that makes a ton of sense I think that's all the time we have here maybe Mike if I can just kind of turn it back to you for any closing remarks you want to give just to say I'm super excited to be with the team if you look at what the Verisim team led by Dan has put together it was like a no brainer had to do this because the advances they're seeing for patients, the opportunity here is just tremendous to create shareholder value and I really feel privileged to be able to be part of the team, so thank you. Got it, awesome, well thank you for being here, thank you everyone in the room. Thank you, good job.
- Company
- VERASTEM INC
- Keywords
- VERASTEM INC